RhumbLine Advisers’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.3M | Sell |
45,140
-897
| -2% | -$254K | 0.01% | 959 |
|
|
2026
Q1 | $12.8M | Buy |
46,037
+641
| +1% | +$185K | 0.01% | 940 |
|
|
2025
Q4 | $13.8M | Sell |
45,396
-3,092
| -6% | -$965K | 0.01% | 916 |
|
|
2025
Q3 | $13.6M | Sell |
48,488
-1,657
| -3% | -$451K | 0.01% | 941 |
|
|
2025
Q2 | $12.1M | Sell |
50,145
-5,265
| -10% | -$1.24M | 0.01% | 978 |
|
|
2025
Q1 | $13.5M | Buy |
55,410
+910
| +2% | +$274K | 0.01% | 885 |
|
|
2024
Q4 | $17.9M | Buy |
54,500
+264
| +0.5% | +$89.6K | 0.02% | 757 |
|
|
2024
Q3 | $18.1M | Buy |
54,236
+19,373
| +56% | +$6.15M | 0.02% | 765 |
|
|
2024
Q2 | $9.52M | Sell |
34,863
-2,457
| -7% | -$715K | 0.01% | 1048 |
|
|
2024
Q1 | $12.9M | Sell |
37,320
-180
| -0.5% | -$59.2K | 0.01% | 934 |
|
|
2023
Q4 | $12.1M | Buy |
37,500
+810
| +2% | +$254K | 0.01% | 959 |
|
|
2023
Q3 | $13.2M | Buy |
36,690
+90
| +0.2% | +$34.7K | 0.02% | 851 |
|
|
2023
Q2 | $13.9M | Sell |
36,600
-850
| -2% | -$346K | 0.02% | 841 |
|
|
2023
Q1 | $17.9M | Buy |
37,450
+936
| +3% | +$438K | 0.02% | 668 |
|
|
2022
Q4 | $15.4M | Buy |
36,514
+1,599
| +5% | +$645K | 0.02% | 721 |
|
|
2022
Q3 | $14.6M | Buy |
34,915
+563
| +2% | +$281K | 0.02% | 689 |
|
|
2022
Q2 | $17M | Buy |
34,352
+4,740
| +16% | +$2.47M | 0.02% | 616 |
|
|
2022
Q1 | $16.7M | Sell |
29,612
-23,582
| -44% | -$14.2M | 0.02% | 667 |
|
|
2021
Q4 | $40.2M | Buy |
53,194
+4,796
| +10% | +$3.59M | 0.05% | 327 |
|
|
2021
Q3 | $36.1M | Sell |
48,398
-22
| -0% | -$16.5K | 0.05% | 337 |
|
|
2021
Q2 | $31.2M | Buy |
48,420
+2,486
| +5% | +$1.51M | 0.04% | 403 |
|
|
2021
Q1 | $26.2M | Sell |
45,934
-1,171
| -2% | -$693K | 0.04% | 470 |
|
|
2020
Q4 | $27.5M | Sell |
47,105
-3,536
| -7% | -$2.01M | 0.04% | 431 |
|
|
2020
Q3 | $26.1M | Sell |
50,641
-4,444
| -8% | -$2.25M | 0.04% | 391 |
|
|
2020
Q2 | $24.9M | Sell |
55,085
-1,854
| -3% | -$818K | 0.04% | 388 |
|
|
2020
Q1 | $20M | Buy |
56,939
+4,557
| +9% | +$1.68M | 0.04% | 395 |
|
|
2019
Q4 | $19.4M | Sell |
52,382
-1,065
| -2% | -$375K | 0.03% | 496 |
|
|
2019
Q3 | $17.8M | Buy |
53,447
+1,915
| +4% | +$625K | 0.03% | 491 |
|
|
2019
Q2 | $16.1M | Sell |
51,532
-214
| -0.4% | -$64.1K | 0.03% | 535 |
|
|
2019
Q1 | $15.8M | Sell |
51,746
-3,416
| -6% | -$922K | 0.03% | 535 |
|
|
2018
Q4 | $12.8M | Buy |
55,162
+15,793
| +40% | +$4.24M | 0.03% | 588 |
|
|
2018
Q3 | $12.3M | Sell |
39,369
-1,633
| -4% | -$507K | 0.02% | 597 |
|
|
2018
Q2 | $11.8M | Sell |
41,002
-3,300
| -7% | -$911K | 0.02% | 609 |
|
|
2018
Q1 | $11.1M | Sell |
44,302
-2,333
| -5% | -$594K | 0.02% | 625 |
|
|
2017
Q4 | $11.1M | Buy |
46,635
+2,056
| +5% | +$498K | 0.02% | 639 |
|
|
2017
Q3 | $9.91M | Buy |
44,579
+2,965
| +7% | +$667K | 0.02% | 678 |
|
|
2017
Q2 | $9.42M | Sell |
41,614
-2,078
| -5% | -$453K | 0.02% | 660 |
|
|
2017
Q1 | $8.71M | Buy |
43,692
+1,507
| +4% | +$290K | 0.02% | 707 |
|
|
2016
Q4 | $7.69M | Buy |
42,185
+1,031
| +3% | +$176K | 0.02% | 739 |
|
|
2016
Q3 | $6.74M | Buy |
41,154
+1,553
| +4% | +$236K | 0.02% | 736 |
|
|
2016
Q2 | $5.66M | Buy |
39,601
+2,451
| +7% | +$350K | 0.02% | 769 |
|
|
2016
Q1 | $5.08M | Buy |
37,150
+720
| +2% | +$94.5K | 0.02% | 827 |
|
|
2015
Q4 | $5.05M | Sell |
36,430
-278
| -0.8% | -$38.5K | 0.02% | 817 |
|
|
2015
Q3 | $4.93M | Buy |
36,708
+1,637
| +5% | +$236K | 0.02% | 822 |
|
|
2015
Q2 | $5.28M | Buy |
35,071
+435
| +1% | +$62.2K | 0.02% | 815 |
|
|
2015
Q1 | $4.68M | Buy |
34,636
+2,597
| +8% | +$322K | 0.01% | 874 |
|
|
2014
Q4 | $3.86M | Buy |
32,039
+1,834
| +6% | +$211K | 0.01% | 937 |
|
|
2014
Q3 | $3.42M | Buy |
30,205
+782
| +3% | +$92.7K | 0.01% | 970 |
|
|
2014
Q2 | $3.52M | Sell |
29,423
-1,906
| -6% | -$233K | 0.01% | 996 |
|
|
2014
Q1 | $4.01M | Sell |
31,329
-236
| -0.7% | -$30.3K | 0.01% | 932 |
|
|
2013
Q4 | $3.9M | Sell |
31,565
-1,323
| -4% | -$161K | 0.01% | 952 |
|
|
2013
Q3 | $3.87M | Sell |
32,888
-10
| -0% | -$1.18K | 0.01% | 942 |
|
|
2013
Q2 | $3.69M | Buy |
+32,898
| New | +$3.86M | 0.01% | 927 |
|
Other funds holding BIO
AI
RhumbLine Advisers's BIO Position: Q2 2026 in Review
RhumbLine Advisers reduced its Bio-Rad Laboratories Class A (BIO) stake by 1.9% in Q2 2026, selling an estimated $254K and leaving 45,140 shares worth $13.3M. The position accounts for 0.01% of the portfolio, ranked #959.
RhumbLine Advisers first reported a position in BIO in Q2 2013 and has held it in 53 quarters since. The position peaked at $40.2M in Q4 2021. 397 funds tracked by Wall St. Rank hold BIO as of Q2 2026.
- RhumbLine Advisers held 45,140 shares of Bio-Rad Laboratories Class A worth $13.3M as of Q2 2026.
- RhumbLine Advisers sold 897 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $254K.
- Bio-Rad Laboratories Class A made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #959 holding.
- RhumbLine Advisers first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 53 quarters since.
- RhumbLine Advisers's Bio-Rad Laboratories Class A position peaked at $40.2M in Q4 2021.
- 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.